Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...

The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that ...

RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...

Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on ...

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...

The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...

Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight ...

The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely ...